Chrysalis BioTherapeutics Receives Additional Funding from the National Institutes of Health for COVID-19 Therapeutic Development
GALVESTON, Texas -- Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company developing regenerative drugs that target vascular endothelial and progenitor cells, announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has provided additional funding in the amount of $587,995 to its contract with Chrysalis, bringing the total contract award to develop TP508 as a therapeutic for COVID-19 patients to $1.5 million.
“SARS-CoV-2 infection can cause significant vascular damage leading to formation of blood clots and multiple organ failure, especially in the elderly and those with preexisting conditions involving endothelial dysfunction,” said Chrysalis CEO Dr. Darrell Carney. “TP508 treatment restores endothelial function and reduces effects of inflammation in animal studies. Therefore, we anticipate that TP508 will reduce COVID-19 progression and mortality in patients with moderate to severe SARS-CoV-2 infections.”
“Funding from the NIAID COVID-19 contract is being used to complete in vivo testing of TP508 efficacy, drug product manufacture, and regulatory steps to initiate clinical trials in COVID-19 patients,” said Chrysalis Executive VP Dr. Laurie Sower. “Based on the drug’s mode of action and its mitigation of vascular damage in other traumatic disease models, TP508 may be a valuable drug to be used in combination with supportive care or antivirals to prevent acute and long-term effects of COVID-19.”
Chrysalis BioTherapeutics, Inc. is a biopharmaceutical development company located in Galveston, TX. TP508 (rusalatide acetate) is licensed from The University of Texas Medical Branch (UTMB) at Galveston, TX. Although TP508 has shown potential efficacy in stimulating early tissue repair in human clinical trials, it is not yet FDA-approved and is currently only available for investigational use. For additional information, contact Dr. Darrell Carney, CEO, at dcarney@chrysbio.com or visit http://www.chrysbio.com.
Research reported in this press release was in whole or part supported with federal funds from NIAID under contract number HHSN272201700011C. The content is solely the responsibility of the authors and Chrysalis BioTherapeutics, Inc. and does not necessarily represent official views of the National Institutes of Health or The University of Texas Medical Branch.
Related news
-
The Indoor Microbiome and Its Impact on Indoor Environmental Quality
Last year, the U.S. Environmental Protection Agency (EPA) announced the release of a new webpage to provide information about the indoor microbiome. All of the living microorganisms inside of an indoor environment, and their by-products, are collectively known as the indoor microbiome. The indoor microbiome that surrounds each of us is diverse and dynamic, made up of bacteria, viruses, fungi and other single-celled organisms. These microorganisms may be growing or inactive, and may be present in different life...
-
Creative BioMart Established a Novel Sub-brand Creative BioMart Recombinant Allergen
Creative BioMart, an internationally recognized leading supplier of recombinant proteins, recently established a novel sub-brand “Creative BioMart Recombinant Allergen” that focuses on allergen-related study. Allergy is a common hypersensitivity disease in the world. It can be treated by allergen-specific immunotherapy (AIT). Natural allergen extracts do not meet the regulatory requirements for the production of allergy vaccines, the allergens are unstable, the number of allergens varies, pollution,...
-
Olansi air purifier review : Can Olansi Air Purifiers Help Avoid Allergies?
This is one of the most questions about air purifiers. Most people wonder if AP air purifiers can help them with allergies. In this article, we are going to talk about this question. The short answer is, yes these units can help avoid allergies caused by dust, dander, and pet hair. Read on to find out. First of all, we should talk about the most common household allergens that can be found in almost every home. Pet Fur Pet fur is one of the most common allergens. In fact, since these allergies are quite...
-
Indee Labs Awarded Grant from the National Institute of Allergy & Infectious Disease
Indee Labs is a biotechnology company developing the µVS Delivery SystemTM for non-viral intracellular or gene delivery. The team at Indee Labs was awarded a grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop the µVS Delivery SystemTM for modified regulatory T cells. “Cellular immunotherapies using regulatory T cells (Tregs) show tremendous promise for the treatment of autoimmune disease, transplant rejection,...
-
Nature Scientific Reports has published a peer reviewed paper showing important immune response benefits associated with AOBiome`s B244 Ammonia Oxidizing Bacteria drug therapy
B244 inhibits Th2 immune polarization in human primary immune cells in both the active and the inactive state. CAMBRIDGE, Mass., July 15, 2021 /PRNewswire/ — AOBiome Therapeutics, Inc. (“AOBiome”), a leading clinical-stage microbiome company focusing on inflammatory conditions, announced new findings indicating a link between Ammonia Oxidizing Bacteria (AOB) and the human immune system. The company’s lead clinical asset, B244, is composed of a unique patented single strain of AOB and is...
Customer comments
No comments were found for Chrysalis BioTherapeutics Receives Additional Funding from the National Institutes of Health for COVID-19 Therapeutic Development. Be the first to comment!